Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

703.30INR
6:15am EDT
Change (% chg)

Rs-0.55 (-0.08%)
Prev Close
Rs703.85
Open
Rs702.90
Day's High
Rs709.80
Day's Low
Rs701.00
Volume
157,693
Avg. Vol
445,281
52-wk High
Rs854.50
52-wk Low
Rs572.40

Latest Key Developments (Source: Significant Developments)

Beijing Science Sun Pharmaceutical unit to pay penalty of 0.3 mln yuan
Friday, 19 Aug 2016 04:05am EDT 

Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>: Says its unit received report of administrative punishment from environmental protection department .Says the unit was ordered to pay penalty of about 0.3 million yuan regarding its wastewater discharge.  Full Article

Sun Pharmaceutical Industries June-qtr consol profit rises almost fourfold
Friday, 12 Aug 2016 04:46am EDT 

Sun Pharmaceutical Industries Ltd : June-quarter consol net profit 20.34 billion rupees . June-quarter consol total income from operations 82.43 billion rupees . June-quarter net profit consensus forecast was 19.04 billion rupees . Consol net profit in June-quarter last year was 5.56 billion rupees as per Ind-AS; consol net sales was 67.61 billion rupees .  Full Article

Sun Pharmaceutical extends Imatinib Mesylate Savings Card program benefits for patients in USA
Monday, 8 Aug 2016 08:32am EDT 

Sun Pharmaceutical Industries Ltd : Sun Pharma extends Imatinib Mesylate Savings Card program benefits for patients in USA . Co will continue to offer up to US$ 700 reduction on each eligible patient's initial out-of-pocket cost from their commercial insurer . Benefit will cover a patient's monthly fills for a 30-day supply of Sun pharma's imatinib mesylate prescribed for ph+cml, . Will also continue hub service wherein patients can call and speak with a trained healthcare professional .  Full Article

India's Sun Pharma gets FDA nod for generic Glumetza
Monday, 1 Aug 2016 11:44pm EDT 

Sun Pharmaceutical Industries Ltd : Sun Pharma announces U.S. FDA approval for generic Glumetza . The commercial launch of the tablets in the U.S. is expected over the next few weeks .  Full Article

Sun Pharma and Almirall signs license deal for Psoriasis treatment
Wednesday, 27 Jul 2016 10:32pm EDT 

Sun Pharmaceutical Industries Ltd : Almirall and Sun Pharma enter into a license agreement for Tildrakizumab in Europe for Psoriasis . To receive development & regulatory milestone payments, royalties, the terms of which are confidential .  Full Article

Almirall signs license deal with Sun Pharma for psoriasis treatment
Wednesday, 27 Jul 2016 11:57am EDT 

Almirall SA : Says enters into a license agreement with Sun Pharma Industries for tildrakizumab in Europe for psoriasis . Says to pay Sun Pharma an initial upfront payment of $50 million . Says Sun Pharma will be eligible to get milestone payments, sales milestone payments and royalties on net sales .Says phase-3 studies of tildrakizumab have recently been completed.  Full Article

Sun Pharma signs 410 mln rupees deal with RPG Life Sciences
Wednesday, 27 Jul 2016 06:57am EDT 

Sun Pharmaceutical Industries Ltd : Signed an agreement with RPG Life Sciences Ltd to divest seven prescription brands in India . Deal for a consideration of 410 million rupees . 7 divested brands include brands used for treatment of respiratory-track infections, urological disorders, cardiovascular diseases and brands in health supplements segment .  Full Article

Sun Pharma Industries gets USFDA nod for generic Crestor
Wednesday, 20 Jul 2016 02:25am EDT 

Sun Pharmaceutical Industries Ltd : Gets final approval from USFDA for generic Crestor .  Full Article

Sun Pharma enters licensing deal for SPARC's Elepsia XR
Sunday, 17 Jul 2016 10:35pm EDT 

Sun Pharmaceutical Industries Ltd : Sparc licenses elepsia xrtm(levetiracetam er tablets) to Sun pharma . Sparc to get up-front payment of $10 million from co . Sparc licenses elepsia xrtm to Sun pharma's unit . Sparc eligible for additional milestone payments, defined royalties linked to future sales of elepsia xr .  Full Article

Sun Pharmaceutical Industries launches Gemcitabine InfuSMART
Sunday, 10 Jul 2016 10:56pm EDT 

Sun Pharmaceutical Industries Ltd : Launches gemcitabine infusmart, ready-to-administer bag for oncology treatment . Product will have shelf life of 2 years . Infusmart rollout starts in europe,planned across 6 countries-netherlands,uk,spain,germany,italy & France over next few months .  Full Article

More From Around the Web

BRIEF-Sun Pharma says filing of tildrakizumab with European Medicines Agency by Almirall

* Says validation of regulatory filing of tildrakizumab with the european medicines agency (EMA) by Almirall.